Earnings Call Summary | Aspira Women's Health(AWH.US) Q4 2023 Earnings Conference
Earnings Call Summary | Aspira Women's Health(AWH.US) Q4 2023 Earnings Conference
The following is a summary of the Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript:
以下是Aspira Women's Health Inc.（AWH）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Aspira achieved a revenue growth of 15% in 2023 driven by its OvaSuite suite of products.
The average full-year OvaSuite test volume per full-time sales representative increased by 50%.
The average unit price grew from $372 in 2022 to $383 in 2023, a sharp increase credited to the improving market access.
The Q4 2023 OvaSuite revenue was $2.1 million, remaining flat when compared to Q4 in 2022, but saw an overall annual growth with OvaWatch and average unit price increase.
Cash used in operating activities decreased significantly by 49% in 2023 compared to the previous year.
受其OvaSuite產品套件的推動，Aspira在2023年實現了15％的收入增長。
每位全職銷售代表的全年平均OvaSuite測試量增長了50％。
平均單價從2022年的372美元上漲到2023年的383美元，這一大幅上漲歸因於市場準入的改善。
2023年第四季度的OvaSuite收入爲210萬美元，與2022年第四季度相比保持不變，但OvaWatch的總體年增長率和平均單價上漲。
與上年相比，2023年用於經營活動的現金大幅下降了49％。
Business Progress:
業務進展：
Aspira is developing AI-based assays to enhance the diagnosis of gynecologic diseases.
Manuscripts discussing the work on OvaWatch are under review for publication.
OvaMDX, a collaboration with the Dana Farber Cancer Institute, is expected to be finalized by the end of 2024.
Progress in endometriosis testing has been positive with the EndoCheck assay development on track together with the development of EndoMDX.
Aspira has introduced Dr. Sandra Milligan as President to expedite their launch plans and secure new innovation and business partnerships.
In 2023, Aspira further expanded its sales territory and team, and plans to continue this expansion into 2024.
With the launching of the first-ever protein-based blood test for diagnosing endometriosis and endometrioma, Aspira has shown transformative innovation, which has garnered significant interest in the medical community.
Aspira正在開發基於人工智能的檢測方法，以增強對婦科疾病的診斷。
討論OvaWatch工作的手稿正在審查中，準備出版。
與達納·法伯癌症研究所合作的OvamDx預計將於2024年底完成。
隨着EndoCheck檢測的開發以及EndomDX的開發，子宮內膜異位症的檢測取得了積極的進展。
Aspira已任命桑德拉·米利根博士爲總裁，以加快他們的啓動計劃並確保新的創新和商業夥伴關係。
2023年，Aspira進一步擴大了其銷售區域和團隊，並計劃將這種擴張持續到2024年。
隨着首個用於診斷子宮內膜異位症和子宮內膜瘤的基於蛋白質的血液檢查的推出，Aspira表現出了變革性的創新，引起了醫學界的濃厚興趣。
More details: Aspira Women's Health IR
更多詳情： Aspira 女性健康 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。